Cargando…

Prognostic Value of High-Sensitivity Modified Glasgow Prognostic Score in Castration-Resistant Prostate Cancer Patients Who Received Docetaxel

SIMPLE SUMMARY: Prostate cancer is one of the most prevalent cancers in men. Prostate cancer is characterized by an early response to hormonal therapy and prostate-specific antigen (PSA) is useful for diagnosis, prognosis, and treatment evaluation. However, if the patient becomes resistant to treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ando, Keisuke, Sakamoto, Shinichi, Saito, Shinpei, Maimaiti, Maihulan, Imamura, Yusuke, Sazuka, Tomokazu, Sato, Nobuo, Komiya, Akira, Anzai, Naohiko, Ichikawa, Tomohiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918602/ https://www.ncbi.nlm.nih.gov/pubmed/33673284 http://dx.doi.org/10.3390/cancers13040773

Ejemplares similares

Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma
por: Higuchi, Kosuke, et al.
Publicado: (2019)

Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma
por: Maimaiti, Maihulan, et al.
Publicado: (2020)

Contribution of LAT1-4F2hc in Urological Cancers via Toll-like Receptor and Other Vital Pathways
por: Zhao, Xue, et al.
Publicado: (2022)

Contribution of the L-Type Amino Acid Transporter Family in the Diagnosis and Treatment of Prostate Cancer
por: Zhao, Xue, et al.
Publicado: (2023)

Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients
por: Kanesaka, Manato, et al.
Publicado: (2021)

Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer
por: Sugiura, Masahiro, et al.
Publicado: (2020)

The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2
por: Maimaiti, Maihulan, et al.
Publicado: (2021)

Successful treatment of metastatic bladder cancer by gemcitabine‐cisplatin re‐challenge after pembrolizumab
por: Arai, Takayuki, et al.
Publicado: (2021)

Machine-learning predicts time-series prognosis factors in metastatic prostate cancer patients treated with androgen deprivation therapy
por: Saito, Shinpei, et al.
Publicado: (2023)

Functional analysis of LAT3 in prostate cancer: Its downstream target and relationship with androgen receptor
por: Rii, Junryo, et al.
Publicado: (2021)

Left ileal conduit: A case report
por: Nakamura, Kazuyoshi, et al.
Publicado: (2019)

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
por: Sakamoto, Shinichi, et al.
Publicado: (2019)

Relationship between Preoperative Pyuria and Bacille Calmette-Guerin Treatment in Intravesical Recurrence after Transurethral Resection of High-Risk, Non-Muscle Invasive, Bladder Carcinoma: A Retrospective Study of Human Data
por: Tsukamoto, Ryo, et al.
Publicado: (2023)

Expression of tertiary lymphoid structure in deferred cytoreductive nephrectomy of metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
por: Sazuka, Tomokazu, et al.
Publicado: (2021)

Cushing's syndrome in pregnancy in which laparoscopic adrenalectomy was safely performed by a retroperitoneal approach
por: Takeuchi, Nobuyoshi, et al.
Publicado: (2023)

A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy
por: Sato, Hiroaki, et al.
Publicado: (2023)

A case of ipsilateral three simultaneous renal cell carcinomas with different histologic types
por: Tanaka, Satoki, et al.
Publicado: (2023)

A case of bladder cancer after bilateral lung transplantation following bone marrow transplantation
por: Arai, Yutaro, et al.
Publicado: (2023)

Tumor localization by Prostate Imaging and Reporting and Data System (PI-RADS) version 2.1 predicts prognosis of prostate cancer after radical prostatectomy
por: Fujimoto, Ayumi, et al.
Publicado: (2023)

Aberrantly expressed PLOD1 promotes cancer aggressiveness in bladder cancer: a potential prognostic marker and therapeutic target
por: Yamada, Yasutaka, et al.
Publicado: (2019)

Tumor Location and a Tumor Volume over 2.8 cc Predict the Prognosis for Japanese Localized Prostate Cancer
por: Baba, Haruki, et al.
Publicado: (2022)

Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy
por: Sazuka, Tomokazu, et al.
Publicado: (2015)

Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy
por: Ohtaka, Ayako, et al.
Publicado: (2019)

The new preparation method for paraffin-embedded samples applying scanning electron microscopy revealed characteristic features in asthma-induced mice
por: Wakai, Ken, et al.
Publicado: (2022)

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
por: Yamashita, Shimpei, et al.
Publicado: (2016)

Prognostic Value of (18)F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel
por: Quaquarini, E., et al.
Publicado: (2019)

Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel
por: Chang, Li-Wen, et al.
Publicado: (2021)

External Validation of a Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Patients Receiving Post-Docetaxel Second-Line Chemotherapy
por: Blas, Leandro, et al.
Publicado: (2022)

Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer
por: Uemura, Koichi, et al.
Publicado: (2016)

Significant prognostic difference between Grade Group 4 and 5 in the 2014 International Society of Urological Pathology Grading System for High Grade Prostate Cancer with Bone Metastasis
por: Yamada, Yasutaka, et al.
Publicado: (2017)

Usefulness of Renal Autotransplantation for Radiotherapy-induced Renovascular Hypertension
por: Wakabayashi, Shinichi, et al.
Publicado: (2019)

Utility of the High-Sensitivity Modified Glasgow Prognostic Scores for Oropharyngeal Carcinoma
por: Iuchi, Hiroyuki, et al.
Publicado: (2021)

The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer
por: Hanai, Nobuhiro, et al.
Publicado: (2018)

Glasgow Prognostic Score and modified Glasgow Prognostic Score and survival in patients with hepatocellular carcinoma: a meta-analysis
por: Lu, Lingling, et al.
Publicado: (2021)

Glasgow prognostic score is a better predictor of the long-term survival in patients with gastric cancer, compared to the modified Glasgow prognostic score or high-sensitivity modified Glasgow prognostic score
por: Hirahara, Noriyuki, et al.
Publicado: (2020)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
por: Chi, K. N., et al.
Publicado: (2016)

Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer
por: Goto, Yusuke, et al.
Publicado: (2017)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer
por: Jiang, X, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bv43l8nkkrkbqbt7cpjmtc7suk